Skip to main content

Table 2 Characteristics of the healthy population used for lisinopril PBPK model development

From: Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model

Population Ethnicity Population Size (n) Proportion of female Age (years) Dose
(mg)
Application References
European 12 0 21–34 2.97 Single IV bolus [41]
5.53
11.20
Caucasians 18 0 21–37 20 Single oral dose [42]
European 28 0 18–42 20 Single oral dose [26]
European 8 0 22–31 20 Single oral dose for 10 days [41]
Neonates to Infants 100 50 0.25–1.0 5 Single oral dose Current study
2.5
1.5
Neonates to toddler 100 50 0.25–1.9 20 Single oral dose
10
5
2.5
1.5
Pre-schools children 100 50 2–5 20 Single oral dose
10
5
2.5
1.5
School children 100 50 5–12 20 Single oral dose
10
5
2.5
1.5
Adolescent 100 50 12–16 20 Single oral dose
10